Gemini Therapeutics has appointed Marc Uknis to serve as its chief medical officer. Uknis was most recently a vice president at Achillion, which was acquired by Alexion Pharmaceuticals (NASDAQ: ALXN) last year. His experience also includes positions at ViroPharma and CSL Behring. Cambridge, MA-based Gemini launched in 2017 to develop treatments for age-related macular degeneration. Its lead therapeutic candidate, a recombinant protein called GEM103, is in early-stage testing.